"When developing new approaches or options to treat disease, it is key that the industry establish and nurture its relationships with target patient organizations, their leaders and members. Exchanging information and providing education about disease
intervention and program development pave the road for clinical trial participation and eventual commercial product interest. How do we maintain enthusiasm in patient populations
yet manage expectations realistically in the face of their urgency and emotion? This interactive panel will dissect the bioethics of communications from the perspectives of industry, patient advocacy and clinical research experts."

Objective1: Identify the top three challenges of this issue from the view of industry, patient advocacy and medical research.

Objective2: "Explore how these differing agendas intersect, using actual examples of successfully (or not) managing patient expectations—and lessons learned."

Objective3: View the issue's long-range impact on the drug development process and reputation assigned to industry through a bioethicist's lens, and consider the issue's value as academic research topic.